These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 22240989

  • 1. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
    Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA.
    Breast Cancer Res Treat; 2012 Jun; 133(2):735-40. PubMed ID: 22240989
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.
    Cancer; 2006 Dec 15; 107(12):2745-51. PubMed ID: 17109443
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 15; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 9. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH.
    Obstet Gynecol; 2006 Sep 15; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [Abstract] [Full Text] [Related]

  • 10. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND, Mitra N, Robson ME, Hurley KE, Chuai S, Goldfrank D, Wadsworth E, Lee J, Cigler T, Borgen PI, Norton L, Barakat RR, Offit K.
    J Natl Cancer Inst; 2005 Sep 21; 97(18):1382-4. PubMed ID: 16174860
    [Abstract] [Full Text] [Related]

  • 11. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL.
    J Clin Oncol; 2004 Mar 15; 22(6):1055-62. PubMed ID: 14981104
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.
    Clin Breast Cancer; 2007 Dec 15; 7(11):875-82. PubMed ID: 18269778
    [Abstract] [Full Text] [Related]

  • 14. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group.
    J Clin Oncol; 2008 Mar 01; 26(7):1093-7. PubMed ID: 18195327
    [Abstract] [Full Text] [Related]

  • 15. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z, Enerbäck C, Wallgren A, Nordling M, Karlsson P.
    Acta Oncol; 2010 Apr 01; 49(3):361-7. PubMed ID: 20151938
    [Abstract] [Full Text] [Related]

  • 16. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.
    Cancer Epidemiol Biomarkers Prev; 2001 May 01; 10(5):467-73. PubMed ID: 11352856
    [Abstract] [Full Text] [Related]

  • 17. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N.
    Am J Hematol; 2005 Mar 01; 78(3):203-6. PubMed ID: 15726604
    [Abstract] [Full Text] [Related]

  • 18. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D, Kuntz KM, Garber JE, Weeks JC.
    N Engl J Med; 1997 May 15; 336(20):1465-71. PubMed ID: 9148160
    [Abstract] [Full Text] [Related]

  • 19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS.
    Oncologist; 1996 May 15; 1(5):326-330. PubMed ID: 10388011
    [Abstract] [Full Text] [Related]

  • 20. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS, Seminsky M, Honeyford J, Doan B, Franssen E, Meschino W, Chart P, Warner E.
    CMAJ; 2001 Apr 03; 164(7):1005-9. PubMed ID: 11314429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.